Naloxone Hydrochloride; Oxycodone Hydrochloride Patent Expiration
Naloxone Hydrochloride; Oxycodone Hydrochloride is Used for managing severe chronic pain when alternative treatment options are inadequate, requiring daily, around-the-clock, long-term opioid treatment. It was first introduced by Purdue Pharma Lp
Naloxone Hydrochloride; Oxycodone Hydrochloride Patents
Given below is the list of patents protecting Naloxone Hydrochloride; Oxycodone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Targiniq | US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | Mar 30, 2025 | Purdue Pharma Lp |
| Targiniq | US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | Mar 30, 2025 | Purdue Pharma Lp |
| Targiniq | US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | Mar 30, 2025 | Purdue Pharma Lp |
| Targiniq | US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | Mar 30, 2025 | Purdue Pharma Lp |
| Targiniq | US9522919 | Oxycodone compositions | Mar 30, 2025 | Purdue Pharma Lp |
| Targiniq | US8846090 | Matrix for sustained, invariant and independent release of active compounds |
Apr 04, 2023
(Expired) | Purdue Pharma Lp |
| Targiniq | US8846091 | Matrix for sustained, invariant and independent release of active compounds |
Apr 04, 2023
(Expired) | Purdue Pharma Lp |
| Targiniq | US9555000 | Pharmaceutical preparation containing oxycodone and naloxone |
Apr 04, 2023
(Expired) | Purdue Pharma Lp |
| Targiniq | US9907793 | Pharmaceutical preparation containing oxycodone and naloxone |
Apr 04, 2023
(Expired) | Purdue Pharma Lp |
| Targiniq | US8969369 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9056051 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9084729 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9161937 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9168252 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9283216 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9283221 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9345701 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US9511066 | Abuse-resistant controlled-release opioid dosage form |
May 10, 2022
(Expired) | Purdue Pharma Lp |
| Targiniq | US6277384 | Opioid agonist/antagonist combinations |
Dec 22, 2018
(Expired) | Purdue Pharma Lp |
| Targiniq | US6696066 | Opioid agonist/antagonist combinations |
Dec 22, 2018
(Expired) | Purdue Pharma Lp |
| Targiniq | US8673355 | Opioid agonist/antagonist combinations |
Dec 22, 2018
(Expired) | Purdue Pharma Lp |
| Targiniq | US8822487 | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec 22, 2018
(Expired) | Purdue Pharma Lp |
| Targiniq | US9205082 | Opioid agonist/antagonist combinations |
Dec 22, 2018
(Expired) | Purdue Pharma Lp |
| Targiniq | US9474750 | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec 22, 2018
(Expired) | Purdue Pharma Lp |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Naloxone Hydrochloride; Oxycodone Hydrochloride's patents.
Latest Legal Activities on Naloxone Hydrochloride; Oxycodone Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Naloxone Hydrochloride; Oxycodone Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 01 Jul, 2024 | US9345701 |
| Expire Patent Critical | 22 Apr, 2024 | US9283221 |
| Expire Patent Critical | 22 Apr, 2024 | US9283216 |
| Maintenance Fee Reminder Mailed Critical | 15 Jan, 2024 | US9345701 |
| Expire Patent Critical | 04 Dec, 2023 | US9168252 |
| Expire Patent Critical | 27 Nov, 2023 | US9161937 |
| Maintenance Fee Reminder Mailed Critical | 06 Nov, 2023 | US9283216 |
| Maintenance Fee Reminder Mailed Critical | 06 Nov, 2023 | US9283221 |
| Expire Patent Critical | 28 Aug, 2023 | US9084729 |
| Expire Patent Critical | 24 Jul, 2023 | US9056051 |
Naloxone Hydrochloride; Oxycodone Hydrochloride's Family Patents
